Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics' stock price has been impacted by several key events over the past six months. In August 2025, the stock plunged due to investor concerns about tolerability issues with its oral obesity drug. In September 2025, institutional investors saw their holdings value drop. In October 2025, the company reported its Q3 earnings, missing the consensus estimate, but some analysts maintained or raised their ratings and price targets. In November 2025, the stock experienced fluctuations due to profit-taking and positive announcements, and Zacks Research upgraded the stock from a "strong sell" to a "hold" rating. As of November 25, 2025, the share price was $35.46, representing a decline of 33.62% from November 26, 2024.

As a clinical-stage biopharmaceutical company, Viking Therapeutics does not currently have commercialized products generating revenue, so there is no demand seasonality for its products or services. The company's financial performance is driven by its progress in clinical trials and its ability to secure funding.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Its pipeline includes VK2809 for NASH and NAFLD, VK2735 for obesity, VK0214 for X-ALD, VK5211, and VK0612. The company leverages its expertise in metabolism and holds exclusive worldwide rights to five therapeutic programs licensed from Ligand Pharmaceuticals Incorporated.

Viking Therapeutics is headquartered in San Diego, California, United States, and its primary operations are research and clinical trials. While its stock is traded on various international exchanges, specific information regarding a global geographic footprint for product sales or commercial operations is not applicable at this clinical stage.

Viking Therapeutics' brand reputation has been largely tied to its clinical trial progress and market perception of its drug candidates, particularly VK2735 for obesity. The promising efficacy of VK2735 has positioned Viking as a strong contender in the GLP-1 market. However, the company faced a stock plunge in August 2025 due to investor concerns over tolerability issues in a Phase 2 trial, highlighting the scrutiny in the competitive obesity drug market.

Viking Therapeutics has a diverse ownership structure, with a significant portion held by institutional investors. Institutions own approximately 69% of the company's shares, with major holders including The Vanguard Group, Inc., Fmr Llc, and BlackRock, Inc. Individual investors hold approximately 29% of the company's ownership. Insiders own around 1.7% of the company's shares, with CEO Brian Lian being a notable individual owner.